文献速递血脂与心血管预防

单基因与多基因家族性高胆固醇血症患者早发动脉粥样硬化性疾病风险

Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

本研究纳入626例临床诊断家族性高胆固醇血症(FH)患者,评估单基因与多基因病因对早发(<55岁)心血管疾病(CVD)事件的影响。结果显示单基因FH与CVD风险显著增加相关(调整HR 1.96,95%CI 1.24-3.12,p=0.004),多基因FH风险与未发现遗传病因者无显著差异;单基因FH合并高LDL-C多基因风险评分者CVD风险最高(调整HR 3.06,95%CI 1.56-5.99,p=0.001)。FH基因检测提供独立于LDL-C水平的预后信息。

要点

  • 单基因FH患者早发CVD风险显著高于多基因FH及无遗传病因者。
  • 单基因FH合并高LDL-C多基因风险评分者早发CVD风险最高。
  • FH基因检测可提供独立于LDL-C水平的预后信息。

核心结论

  • 单基因FH叠加高LDL-C多基因风险评分的患者早发CVD风险最高。
  • FH基因检测提供独立于LDL-C水平的重要预后信息。

研究设计与样本

  • 研究对626例根据荷兰脂质诊所网络标准诊断为「可能」「很可能」或「确定」FH的患者进行靶向测序及常见遗传变异分析以计算多基因评分。
  • 多基因评分≥80百分位者定义为多基因FH。
  • 研究终点为不稳定心绞痛、心肌梗死、冠状动脉血运重建或卒中。

主要发现

  • 单基因FH与CVD风险显著增加相关(调整HR 1.96,95%CI 1.24-3.12,p=0.004)。
  • 多基因FH患者CVD风险与未发现遗传病因者无显著差异。
  • 单基因FH患者中,高LDL-C多基因风险评分进一步增加CVD风险(调整HR 3.06,95%CI 1.56-5.99,p=0.001)。

临床怎么用

  • 对临床诊断FH的患者进行基因检测以区分单基因与多基因病因,有助于风险分层。
  • 对单基因FH患者可考虑评估LDL-C多基因风险评分以识别早发CVD极高危者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A pathogenic variant in LDLR, APOB, or PCSK9 can be identified in 30% to 80% of patients with clinically-diagnosed familial hypercholesterolemia (FH). Alternatively, ∼20% of clinical FH is thought to have a polygenic cause. The cardiovascular disease (CVD) risk associated with polygenic versus monogenic FH is unclear. OBJECTIVES: This study evaluated the effect of monogenic and polygenic causes of FH on premature (age <55 years) CVD events in patients with clinically diagnosed FH. METHODS: Targeted sequencing of genes known to cause FH as well as common genetic variants was performed to calculate polygenic scores in patients with "possible," "probable," or "definite" FH, according to Dutch Lipid Clinic Network Criteria (n = 626). Patients with a polygenic score ≥80th percentile were considered to have polygenic FH. We examined the risk of unstable angina, myocardial infarction, coronary revascularization, or stoke. RESULTS: A monogenic cause of FH was associated with significantly greater risk of CVD (adjusted hazard ratio: 1.96; 95% confidence interval: 1.24 to 3.12; p = 0.004), whereas the risk of CVD in patients with polygenic FH was not significantly different compared with patients in whom no genetic cause of FH was identified. However, the presence of an elevated low-density lipoprotein cholesterol (LDL-C) polygenic risk score further increased CVD risk in patients with monogenic FH (adjusted hazard ratio: 3.06; 95% confidence interval: 1.56 to 5.99; p = 0.001). CONCLUSIONS: Patients with monogenic FH and superimposed elevated LDL-C polygenic risk scores have the greatest risk of premature CVD. Genetic testing for FH provides important prognostic information that is independent of LDL-C levels.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Trinder M, Li X, DeCastro ML, et al. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. J Am Coll Cardiol. 2019. PMID: 31345425. doi:10.1016/j.jacc.2019.05.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。